<DOC>
	<DOCNO>NCT00295620</DOCNO>
	<brief_summary>The study assess effect 2 year vs 5 year adjuvant treatment anastrozole initial 5 year adjuvant endocrine therapy .</brief_summary>
	<brief_title>Secondary Adjuvant Long Term Study With Arimidex</brief_title>
	<detailed_description>ABCSG 16 S.A.L.S.A assess effect 2 year vs 5 year adjuvant treatment anastrozole initial 5 year adjuvant endocrine therapy . S.A.L.S.A . randomize open multicentered phase III study compare efficacy secondary adjuvant endokrine treatment Arimidex® ( Anastrozol ) 2 5 year primary adjuvant endokrine therapy patient hormonreceptor positive mammakarzinom . Patients examine screen , 6 month , every year 5 year . The subsequent yearly follow mammographie clinical examination end 10 year screen . S.A.L.S.A . start February 2004 recruit 3484 patient June 2010 78 site Austria . Primary Endpoint : 1 . Proof effect 2 year versus 5 year Anastrozol 5 year adjuvant endocrine therapy disease free survival Secondary endpoint : 1 . Proof effect 2 year versus 5 year Anastrozol 5 year adjuvant endocrine therapy overall survival 2 . Comparison fracture rate therapy group 3 . Comparison incidence 1. secondary carcinoma except contralateral mammacarcinoma 2. contralateral mammacarcinoma therapie group</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Inclusion criterion : 1 . Postmenopausal patient histologically confirm , local radically treat invasive minimalinvasiv Mammacarcinom without previous chemotherapie and/or radiotherapie . 2 . No distant metastasis randomization 3 . No relapse randomization 4 . TNM classification time diagnosis : T13 , N0 N+ , M0 5 . Estrogen progesterone positive beginningof primary endocrine therapy 6 . Endocrine therapy 5 year ( maximum deviation ±12 month ) 7 . Therapy break ( preliminary therapie ) maximum 12 month . 8 . Informed Consent randomisation Exclusion criterion : 1 . Premenopausal patient patient non definable menopausal statusat time randomisation 2 . Apparent secondary malignant tumor status secondary malignant tumor ( Exceptions : simultaniously appear bilateral breast carcinoma , estrogen progesteronereceptor positive side time diagnosis ; situ carcinomaof cervix basal cell carcinoma skin ) 3 . General contraindication respectively hypersensitivity Anastrozol . 4 . Insitu carcinoma size without Mb . Paget Mamilla respectively T4 tumor time first diagnosis . 5 . Receptor unknown negative time diagnosis respectively begin primary endocrine therapy 6 . Known liver and/or kidneyinsufficiency 7 . Performance Index &gt; 2 accord WHO 8 . Regular intake hormon supplement well Hormone Replacement Therapy ( HRT ) 6 month since primary surgery mamma carcinoma 9 . Serious accessory disease , prevent adjuvant therapy accord protocol and/or regular followup care . 10 . Lacking compliance patient 11 . Legal incompetence and/or circumstance , prevent patient understanding nature , mean consequence clinical trial 12 . Existing psychiatrical diseaseaccording ICD ( especially alcohol addiction ) et time admission study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hormone receptor positive breast cancer</keyword>
</DOC>